Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18942284 | 0.89 | HPGD (0.55) | SLC6A2SLC6A4HPGDCYP1A2GAA | |
| SCHEMBL18942207 | 0.88 | HPGD (0.51) | SLC6A2SLC6A4HPGDGAARAB9A | |
| SCHEMBL18941761 | 0.88 | HPGD (0.51) | SLC6A2SLC6A4HPGDGAARAB9A | |
| SCHEMBL18941759 | 0.85 | HDAC3 (0.47) | HPGDCYP1A2CYP2C19RAB9ANPC1 | |
| SCHEMBL18942350 | 0.85 | OPRM1 (0.47) | HPGDATM | |
| SCHEMBL18941691 | 0.85 | HDAC3 (0.47) | HPGDRAB9ANPC1SMN1; SMN2HDAC1 | |
| SCHEMBL18942259 | 0.84 | OPRM1 (0.46) | SLC6A2SLC6A4HPGDRAB9ANPC1 | |
| SCHEMBL18942040 | 0.83 | HPGD (0.54) | HPGDRAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL18941755 | 0.82 | NPC1 (0.50) | HPGDGAARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL18942356 | 0.81 | KDM4E (0.56) | HPGDRAB9ANPC1SMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023602-B2 | Hamamelitannin analogues and uses thereof | UNIVERSITEIT GENT (BE) | 2018-07-17 | — | — | US | disclosed |
| US-20170158727-A1 | HAMAMELITANNIN ANALOGUES AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023602-B2 | Hamamelitannin analogues and uses thereof | PIGS, HAMP, HTT | SLC6A2 4632/4885SLC6A4 4685/4885HPGD 190/4885 |
| US-20170158727-A1 | HAMAMELITANNIN ANALOGUES AND USES THEREOF | PIGS, HAMP, HTT | SLC6A2 4632/4885SLC6A4 4685/4885HPGD 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.